Patients with a t(9;11) translocation (MLL-AF9) develop acute myeloid leukemia (AML), and while in mice the expression of this fusion oncogene also results in the development of myeloid leukemia, it is with long latency. To identify mutations that cooperate with Mll-AF9 we infected neonatal wild type (WT) or Mll-AF9 mice with a Murine Leukemia Virus (MuLV). MuLVinfected Mll-AF9 mice succumbed to disease significantly faster than controls presenting predominantly with myeloid leukemia while infected WT animals developed predominantly lymphoid leukemia. We identified 88 candidate cancer genes near common sites of proviral insertion. Analysis of transcript levels revealed significantly elevated expression of Mn1, and a trend towards increased expression of Bcl11a and Fosb in Mll-AF9 murine leukemia samples with proviral insertions proximal to these genes. Accordingly, FOSB and BCL11A were also over-expressed in human AML harboring MLL gene translocations. FOSB was revealed to be essential for growth in mouse and human myeloid leukemia cells using shRNA lentiviral vectors in vitro. Importantly, MN1 cooperated with Mll-AF9 in leukemogenesis in an in vivo bone marrow viral transduction and transplantation assay. Together, our data identified genes that define transcription factor networks and important genetic pathways acting during progression of leukemia induced by MLL fusion oncogenes.
Introduction
The MLL (mixed lineage leukemia or myeloid/lymphoid leukemia) gene found on chromosome 11q23 is involved in oncogenic translocations in adult and infant leukemia. 1 Translocations involving MLL are also frequently found in therapy-related leukemia when patients have received topoisomerase II inhibitors as part of their treatment.
2 MLL is reported to be involved in translocations with over 60 genes, all of which are thought to result in fusion proteins.
3
The MLL-AF9 translocation, t(9;11)(p22;q23), is the most common MLL translocation observed in patients with de novo and therapy-related AML and indicates an intermediate to poor
prognosis with a high-risk of relapse. 4 ,5 A knock-in mouse model for the MLL-AF9 translocation was generated and mice heterozygous for the Mll-AF9 knock-in allele were reported to develop AML, with 50% of the mice developing disease by five months of age. [6] [7] [8] However, mice presented with leukemia only after a relatively long latency, indicating that cooperating mutations are needed to contribute to leukemia progression.
Murine leukemia viruses (MuLV) have been used to identify important leukemiaassociated genes in various leukemia-predisposed mutant strain backgrounds, such as Eµ-Myc,
Cdkn2a
(-/-) , inversion 16, and Nf1 -/+ mouse models. 9,10,11 A recombinant MuLV that induces myeloid leukemia with a broad tropism in inbred mouse strains has been engineered by combining sequences from the amphotropic virus strain 4070A and Moloney murine leukemia virus (Mo-MuLV), designated MOL4070LTR. 12 MOL4070LTR (abbreviated here as M4070)
functions as an insertional mutagen to accelerate leukemia in at least two mouse models of AML. 13, 14 . Here we use M4070 to identify mutations that collaborate with Mll-AF9 to drive leukemogenesis in mice. To identify genes relevant to human MLL leukemia, a comparative
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Sequence processing and annotation. 26,160 initial ABI sequence reads were processed and analyzed using a custom, semi-automated processing pipeline first described in Starr et al., 2009 . 15 Non-redundant (NR) insertion positions were annotated using the EnsEMBL API 16 with the name of the gene whose start site was closest to the proviral insertion position. CIS positions were annotated similarly using the median insertion position within the CIS as a reference point.
See supplemental methods.
Quantitative real-time PCR. See supplemental methods.
Lentiviral production and shRNA knockdown analysis. 293T cells were transfected with TRIPZ lentiviral shRNAmir plasmids from Open Biosystems (Thermo Fisher Scientific, Waltham, MA) encoding shRNA to the human FOSB gene or a scrambled control. Lentiviral supernatant was collected after 24 and 48 hours, filtered with a 45 µM filter, and concentrated using the LentiX Concentrator (Clontech, Mountain View, CA). U937 leukemia cells. 17, 18 were transduced with the lentivirus for 6 hours, followed by puromycin selection to produce cell lines that stably express the shRNA plasmid. To induce knockdown with the shRNA, cells were plated at 0.5 million cells per well in 6-well plates with 2 mLs of media containing puromycin for 24 hours. The cells were then treated with 4 µg/µL doxycycline to induce the shRNAs.
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Transduction of Tet-On MLL-AF9;Nras
G12D cells and shRNA induction. Experiments were performed as previously described.
19
Western blot analysis. Cells were incubated with lysis buffer for 20 minutes on a rotator and centrifuged at 14,000 RPM for 10 minutes, both at 4 degrees. Samples were analyzed with a
Bradford reaction and 40 µg of total protein were run with sample buffer on a prepared 10% BisTris gel using an Invitrogen gel box at 200 volts and transferred to a nitrocellulose membrane using the iBlot system (Invitrogen). Membranes were blocked with 5% non-fat milk, incubated with anti-Fosb rabbit polyclonal antibody (Cell Signaling Technology, Danvers, MA), and antirabbit secondary antibody (Dako, Carpinteria, CA) before developing using ECL (Thermo Scientific). retroviruses encoding either pSF91-MN1 or a GFP-only construct) 20 were sub-lethally irradiated and plated in nutrient rich medium with a cytokine cocktail of 10 ng/mL mouse recombinant interleukin-6 (mIL-6), 50 ng/mL murine recombinant stem cell factor (mSCF) (Invitrogen), and 5 ng/mL murine recombinant interleukin-3 (mIL-3) (Thermo Fisher Scientific). Twenty-four hours later, the bone marrow cells were added with 5 µg/mL polybrene (Millipore, Billerica, MA). After 48 hours, bone marrow cells were collected and replated for expansion for 24 hours in nutrient-rich media. Recipient 8-week-old C57BL/6J.BoyJ mice were lethally irradiated at 900 Rads the day before being injected intravenously with 10 6 transduced bone marrow cells
Bone Marrow
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Results
Infection with M4070 retrovirus accelerates leukemia development in Mll-AF9/+ mice F1 animals, heterozygous for Mll-AF9 or WT, were generated as shown ( Figure 1A ).
Neonates were injected intraperitoneally with the M4070 virus or mock infected. 21 Ninety-eight percent of the animals in both M4070-infected groups and the mock-infected Mll-AF9 group succumbed to overt leukemia within one year. Infected Mll-AF9 mice had a significantly decreased latency of disease with a median survival of 108 days compared to 165 days in noninfected Mll-AF9 mice (P < 0.0001). Infected WT mice also developed leukemia but with a much longer latency (191 days median survival) compared to the infected Mll-AF9 group (P < 0.0001) ( Figure 1B ). Interestingly, Mll-AF9 female mice died significantly faster than their male littermates, regardless of whether they were injected with the M4070 virus or not (Supplemental Figure 1A -B). This finding may be related to the higher frequency of MLL rearrangements observed in human female infant leukemia.
22
Virally-infected Mll-AF9/+ mice develop predominantly myeloid leukemia Moribund mice that died within one year presented with hematopoietic malignancies, often exhibiting splenomegaly, enlarged lymph nodes, thymus, and occasionally liver. Noninfected Mll-AF9 mice showed 75% myeloid disease, characterized by a high Gr-1 and/or Mac-1 population, and 25% with distinct myeloid and lymphoid populations (MandL). The mixed myeloid and lymphoid disease in this Mll-AF9 model is a novel discovery not described in previous reports. Phenotypic analysis revealed different lineage distribution upon infection with
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From M4070. Forty-four percent of infected Mll-AF9 mice exhibited myeloid disease, 32% MandL, and only 17% had lymphoid disease. Conversely, the vast majority of the infected WT mice presented with lymphoid disease (82%), 10% showed myeloid disease, and only 6.4% of mice had MandL mixed disease ( Figure 1C ). The lymphoid populations were characterized by an extra-thymic high CD4+ or CD8+ single-positive population, or dominant CD4+ and CD8+ double-positive population in the spleen or lymph nodes (Supplemental Figure 3B and data not shown). This defines the first of two distinct classes of lymphoid disease in both virally infected groups, herein called L-1 ( Figure 1C ). The second class of mice were found to have T cell lineage lymphoid disease by immunohistochemistry but also expressed the Mac1 myeloid marker on the blast cell surface, herein called L-2, a phenotype not found in non-infected Mll-AF9 animals ( Figure 1C ). The total number and percent of mice with each phenotype classification from each experimental cohort is shown in Supplemental Figure 2A .
A common method to determine lineage is to assess T-cell or B-cell receptor rearrangements. However, when we examined leukemias in all three cohorts (infected Mll-AF9, non-infected Mll-AF9, infected WT) for clonal Jß1 or Jß2 (T-cell) or JH (B-cell) receptor gene rearrangements, we frequently saw evidence of TCR and/or BCR rearrangements even if they were phenotypically determined to be myeloid disease. In fact, most Mll-AF9 mice had myeloid disease but almost 50% of myeloid tumors were positive for clonal TCR or BCR rearrangements.
Moreover, 20% of animals with lymphoid disease were negative for clonal T-or B-cell rearrangements (Supplemental Figure 2B ). Thus the presence or absence of a TCR and/or BCR rearrangement is neither completely sensitive nor specific to a lymphoid phenotype and is on its own insufficient to assess lineage. To determine which phenotype qualifiers were statistically significantly associated, Fisher's Exact Tests were performed on each pair-wise comparison of Table 1A) . A myeloid or MandL phenotype was positively correlated with a larger spleen weight, the Mll-AF9/+ genotype, and only in the case of myeloid disease, an extremely elevated WBC count whereas there were multiple reciprocal positive correlations between lymphoid phenotypes, B-and/or Tcell receptor rearrangements, a normal spleen weight, and WT leukemias. Survival curves were generated to determine if the reduced latency in M4070 infected Mll-AF9 mice was associated with a particular phenotype. The survival of Mll-AF9 mice was Figure 1C-1E) . Importantly, the disease latency did not show dependence on phenotype within the WT or Mll-AF9 groups of mice (Supplemental Figure 1F-H) . Thus, the genetic mutations induced by the M4070 virus influenced leukemia progression as governed by the initiating mutation. Therefore, infection accelerated mostly myeloid leukemia Mll-AF9/+ mice, while causing mostly lymphoid leukemia in WT mice.
Cloning retroviral integrations leads to identification of common insertion sites (CISs)
Ligation-mediated PCR was used to amplify the M4070-genomic DNA junctions in 165 independent M4070-infected leukemia samples (both Mll-AF9 and WT). A total of 1,745 nonredundant insertions or unique reference sequences, representing an average of 10.8 insertions per tumor, were recovered. Sequences are available through the public mouse Retroviral Tagged Cancer Gene Database (RTCGD). 23 In total, 88 unique CISs were identified by established statistical analysis and the additional criterion that proviral insertions in leukemia samples must come from at least 3 mice (see supplemental methods) ( Table   2 ), and Mll-AF9 leukemia group (Supplemental Table 3 ) overlapped with the combined dataset.
Southern blotting using an M4070-specific probe showed that the proviral insertions in infected animals were clonal to oligoclonal with one internal proviral fragment represented by a band common to all tumors and additional unique M4070 insertions (Supplemental Figure 4) . No proviral insertions were detected in non-infected animals and M4070 insertions were consistent throughout each diseased animal (data not shown).
The CISs were distributed throughout the mouse genome ( Figure 2A Table 4A ). In addition, the top five overrepresented canonical pathways from this list of candidate genes are linked to acute and chronic myeloid leukemia genes (Supplemental Table 4B ). Figure 4C ). The significant associations between phenotype variables and specific candidate genes are listed in Supplemental Table 1B . Several genes associated with myeloid disease or Mll-AF9 mice (Gmfg, Bcl11a, Mn1) were positively associated with a high spleen weight or high WBC count. As expected, several genes already shown to be associated with the WT genotype and lymphoid disease such as Rasgrp1, Rras2, and Notch1 were also associated with Jß1 or Jß2 rearrangement. Fisher's exact tests were also performed between each candidate gene pair to determine if two genes occurred more frequently together than would be expected by chance. These connections are also included in the enrichment network ( Figure 4C ). Taken together, these data led us to pursue Mn1, Fosb, and Bcl11a for further study as potential MLL-AF9 cooperating genes.
Analysis of candidate leukemia genes leads to identification of

Candidate leukemia genes have aberrant expression in human leukemia
To determine the relevance of the genes detected in this screen in human leukemia, we compared our CIS-associated candidate genes with published data on gene expression and copy number in human leukemia samples. First, we used gene expression profile (GEP) analysis performed on data from a cohort of 461 patients with AML 26, 27 to look for expression of the human homologs of our top three candidate MLL-AF9 cooperating genes: FOSB, MN1, and
BCL11A.
We found expression of all three genes in AML patients at varying levels, illustrating the heterogeneity of gene expression in human AML (Supplemental Figure 5A ). MN1 expression was low overall in human AML but higher on average in 2 AML subsets: patients with 3q rearrangements and inversion 16 patients. The inversion 16 observation is consistent with a previous publication. 28 Expression of FOSB was detected in approximately 50% of AML patients analyzed with either MLL-AF9 translocations or with other 11q23 translocations.
BCL11A was also expressed in all MLL rearranged AMLs at varying levels (Supplemental Figure   5B ).
We then analyzed expression in a subset of the primary AMLs with MLL rearrangements. 27 No significant differences in mean expression for FOSB and BCL11A were observed in patients with MLL-AF9 AMLs or other MLL rearrangements compared to normal total bone marrow (TBM) and CD34+ cells ( Figure 5A ). However, in the case of each gene, some leukemia samples had higher expression than the highest expressing TBM and/or CD34+ we found that eleven of our candidate genes overlap with eight different areas of chromosomal deletion ( Figure 5B ), suggesting some pathways may be deregulated in lymphoid leukemia at least in part by deletion. There were also two regions of chromosomal gain that overlapped with two of our candidate leukemia genes ( Figure 5C ). One is a novel gene (AC157924.6) and the other is MYB, the amplification of which has been implicated in lymphoid and myeloid leukemia development. 30, 31 Similarly, one CIS overlapped with a region of chromosomal gain containing MYB when using data from human AML samples collected at Washington University in St.
Louis. 32 However, minimal recurring copy number alterations were found in human AML overall, suggesting other mechanisms may lead to aberrant AML gene expression, such as epigenetic modifications.
Candidate MLL-AF9 cooperating genes have aberrant expression in mouse myeloid leukemia samples
To confirm that proviral insertions affect expression of CIS-associated candidate genes in leukemia samples with insertions near those genes, we compared expression to leukemia samples that do not contain proviral insertions near these genes. Intron-spanning primers were designed for 15 candidate genes and quantitative real time PCR (qRT-PCR) was performed on RNA isolated from leukemias and from the corresponding tissue (lymph nodes, thymus, or spleen) from normal WT animals as baseline. Notably, Mn1 expression was significantly increased in
Mll-AF9 myeloid leukemia tissues with insertions near Mn1 compared to Mll-AF9 myeloid leukemia tissues without insertions near Mn1 (P < 0.05) ( Figure 6A ). In this case, we found that distal insertions 100 KB downstream of Mn1, but near a novel gene called C130026L21Rik, also affected Mn1 expression. A trend towards increased expression in myeloid leukemia from mice with insertions near Fosb and Bcl11a was also observed (Figure 6B-C). We found that Rras2 (P < 0.05) and Notch1 (P < 0.05) expression was significantly increased in infected WT leukemic tissues with insertions near those specific genes compared to infected WT leukemic tissues without insertions near those genes (data not shown).
Functional validation of candidate genes cooperating with MLL-AF9 in AML leukemogenesis
To validate the importance of FOSB in MLL-AF9 leukemia, we down-regulated 
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One of the goals of this paper was to accurately define the phenotype of each mouse by collecting extensive complementary data using several established methods. For example, Tand B-cell receptor gene rearrangement status has often been used to diagnose lymphoid leukemia without other data. Here, we show that this approach may be inadequate and that other methods must also be taken into account. Furthermore, about half of the mice with leukemia had a normal WBC count, thus an analysis of circulating cells also cannot be used alone to determine phenotype. However, enlargement of tissues was a reliable way to grossly define myeloid leukemia. Almost all mice with myeloid disease had a significantly higher than normal spleen weight, often presenting with over 10-fold enlargement, while mice with lymphoid leukemia tended to have an enlarged thymus. Flow cytometry was the main method used to define the phenotype of the mice, but was complemented with histology and immunohistochemical analyses to avoid misclassification. There were several cases in which the disease appeared to have a clear phenotype by flow but only advanced methods revealed the entire pathology of the animal, such as the L-2 animals, which had a lymphoid pathology with a myeloid surface marker. Thus, M4070 infection can induce multiple and complex phenotypes, which must be carefully scrutinized in order to make meaningful conclusions about the corresponding CISassociated genes.
The use of M4070 to accelerate myeloid leukemia has been established. 14, 36 Similarly, we also detected leukemia acceleration in a myeloid leukemia-predisposed background and identified a longer list of CISs, all of which have at least three insertions in three mice/leukemias.
Several candidate genes observed in other MuLV-induced AML models such as Bcl11a, Mn1,
and Myb were found in our list. As expected, CIS-associated candidate genes identified almost exclusively in the infected WT cohort presenting with T-cell ALL were known T cell leukemia postulating that MN1 may also be an important AML cancer gene depending on the genetic context. These data are consistent with findings that over-expressing MN1 is sufficient to cause AML in mice. 20 Mn1 has also been identified as a CIS and cooperator with NUP98-HOXD13
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